Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children with Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations

Next Previous
Search
Trial Profile

A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children with Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OTOF GT (Primary)
  • Indications Deafness
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AUDIOGENE
  • Sponsors Sensorion

Most Recent Events

  • 25 Apr 2025 According to a Sensorion media release, company will present data from this study at the annual meeting of the American Society of Pediatric Otolaryngology (ASPO) being held in Montreal, Canada, on April 30 - May 3, 2025.
  • 14 Mar 2025 According to a Sensorion media release, the company plans to complete recruitment of the second cohort of patients and on hosting a KOL event to present new data in H1 2025.
  • 21 Feb 2025 According to a Sensorion media release, Recruitment of the second cohort (three patients) is expected to be completed by the end of the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top